| Oct 8 |
Cue Biopharma (NASDAQ:CUE) adds US$31m to market cap in the past 7 days, though investors from three years ago are still down 89%
|
| Oct 4 |
Cue Biopharma stock rallies nearly 40% on upcoming presentations
|
| Oct 4 |
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
|
| Sep 27 |
Cue Biopharma prices $12M stock offering
|
| Sep 27 |
Cue Biopharma Announces Pricing of $12.0 Million Public Offering
|
| Sep 27 |
Cue Biopharma Announces Proposed Public Offering
|
| Sep 26 |
Cue biopharma announces proposed public offering
|
| Sep 9 |
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
|
| Sep 3 |
Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference
|
| Aug 20 |
Cue Biopharma, Inc. (CUE) Q2 2024 Earnings Call Transcript
|
